 |
ICR Healthcare handled Boston-based cancer drug developer Aktis Oncology as it upsized its initial public offering due to robust investor demand.
Reuters noted the bullish demand for the company’s shares, which is the first public offering during the new year. Gross proceeds from the offering is about $320M.
Aktis is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies.
Eli Lilly, which bought about $100M of Aktis' shares anchored the IPO. Aktis has a strategic collaboration with Lilly to leverage its miniprotein platform to develop novel radioconjugates outside of Aktis’ proprietary pipeline.
ICR Healthcare’s Sean Leous worked the media for the IPO, while Peter Vozzo handled the investor community.
For more insight into healthcare communications, consult O'Dwyer's CPA-verifed rankings of the top healthcare PR firms.
The Blueshirt Group handles Lime as the San Francisco-based electric bike/scooter company has filed paperwork for an initial public offering, which will have an expected valuation in the $2B range.
Why CEOs need their CFOs and CCOs on the same page.
ICR handles Rare Earths Americas as the Manchester, Georgia-based company plans an initial public offering valued in the $370M range.
DGA Group handles takeover target Intertek as the London-based quality assurance testing company as it launches a strategic review of its operations.
